Nov 15, 2019

Time to rethink endpoints for new antiretroviral regimen registration? HIV RNA re-suppression in the ADVANCE trial

Toby PepperrellAndrew Hill


: In the ADVANCE study of first-line treatment, there were 48 participants with HIV RNA ≥50 copies/mL in the week 48 window who had subsequent follow-up data available with no change in randomised treatment. More participants achieved virological re-suppression in the TAF/FTC/DTG and TDF/FTC/DTG arms (26/34, 76%) than on TDF/FTC/EFV (6/14 = 43%) (p = 0.0421). It is unclear whether participants with HIV RNA ≥50 copies/mL at week 48 should be termed 'virological failures' on integrase inhibitor-based treatment.

  • References13
  • Citations


  • This paper may not have been cited yet.

Mentioned in this Paper

First-Line Therapy
SRY gene
Integrase Inhibitors
Antiretroviral Therapy
HIV Infections
Clinical Trials
Follicular Thyroid Carcinoma

Related Feeds

AIDS Malignancies

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

Related Papers

The European Respiratory Journal
Jakko van Ingen, Richard M Anthony
The Australian and New Zealand Journal of Psychiatry
Philip Boyce
© 2020 Meta ULC. All rights reserved